Aspen Pharmacare EBITDA to More Than Double in 2027

The pharmaceutical group expects strong growth in 2027 following operational changes in South Africa and France.

Updated on Oct. 27, 2026 in Corporate Finance

Isometric editorial illustration of a clean room production line, representing industrial growth in the pharmaceutical manufacturing sector. — Aspen Pharmacare forecasts its manufacturing EBITDA to more than double in 2027 following successful operational shifts at its French and South African facilities. AI Illustration. Upload story photo >

Live Poll

Do you trust that pharmaceutical companies can maintain consistent growth after losing major supply contracts?

Aspen Pharmacare forecasts its manufacturing EBITDA to more than double in the 2027 financial year. The company is pivoting after operational shifts in sterile facilities helped offset the loss of a terminated mRNA contract.

Why it matters

The projected earnings growth highlights the effectiveness of Aspen's recent strategy to reconfigure its sterile manufacturing operations. By installing new production lines, the firm aims to capitalise on new contracts to drive long-term financial stability.

Aspen reported a 21% increase in manufacturing EBITDA to R828 million, despite a 10% decline in manufacturing revenue to R9.5 billion for the year ending June 2026. The group also increased its dividend to 232 cents per share.

The players

Aspen Pharmacare

A South African multinational pharmaceutical company that specialises in the manufacture and distribution of a wide range of generic and branded medicines.

The details

Aspen successfully implemented operational changes in its sterile finished-dose-form facilities in France and South Africa to compensate for lost mRNA contract work. The firm also secured new revenue streams through the start of commercial insulin vial production in May 2026.

The 2025 financial year saw an mRNA contract contribute R1 billion to manufacturing EBITDA.
Aspen settled an mRNA contract dispute for 25 million euro in October 2025.
Commercial production of insulin vials in South Africa began in May 2026.
The 2026 financial year concluded in June 2026.
Aspen expects manufacturing EBITDA to more than double in the 2027 financial year.

Market Landscape

Aspen is realigning its manufacturing portfolio to reduce dependency on volatile short-term contracts following the 2025 financial year termination of its mRNA production agreement. This shift positions the company to better compete in the global sterile pharmaceutical market.

Shareholders may benefit from the company's increased dividend of 232 cents per share as the firm improves its operational margins. The long-term stability of the company's manufacturing division remains a key factor for retail investors tracking the stock.

The takeaway

Aspen's ability to repurpose its manufacturing infrastructure illustrates how established firms can navigate contract losses through rapid operational pivots. Investors should monitor how the company integrates its new insulin production lines into its broader revenue strategy.